[Click eStock] "SK Biopharm, Epilepsy Drug 'Xcopri' US Sales Increase"

KB Securities has newly set the target price for SK Biopharm at 140,000 won, which is 40% higher than the current stock price. This reflects the continuous growth in U.S. sales of the epilepsy treatment drug, Xcopri.

Smart device linked with SK Biopharm's epilepsy management AI platform 'Zero'

Hye-min Kim, a researcher at KB Securities, stated, "U.S. sales of Xcopri are continuously trending upward, and future expansion of sales is expected through the introduction of follow-up new drugs."

According to KB Securities, the number of prescriptions for direct sales of Xcopri in the U.S. reached approximately 31,000 in September. This is about 2.2 times the 53-month average of competing new drugs. Xcopri's sales this year are expected to reach the upper end of the previous forecast of $300 million to $320 million.

Researcher Kim evaluated, "Xcopri is expected to show annual sales performance at a level that can cover fixed costs of about 400 billion won as a single product," adding, "This means it has entered a full-fledged growth trajectory."

He also noted, "SK Biopharm has proactively invested in radioactive pharmaceuticals and protein degraders in line with global trends, significantly enhancing its research and development (R&D) capabilities," and predicted, "If new drug results emerge in the future, the corporate value will increase further."

This content was produced with the assistance of AI translation services.